Should You Buy Perrigo Company plc Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Perrigo Company plc (PRGO) occupies a solid middle-ground position with a Quality of Company score of 5.9/10. At the current market price of $13.56, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 6 of 7 CirclFi valuation models project upside for Perrigo Company plc (PRGO) at $13.56 — the model consensus leans bullish, with a Quality Score of 5.9/10 and Value-Trap risk of 34/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Perrigo Company plc (PRGO) in 2026?
What Is the Bull Case vs the Bear Case for Perrigo Company plc (PRGO)?
| Bull case — $50.27 target (+270.7%) | Bear case — $3.30 target (-75.6%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, 6 of 7 models identify upside from $13.56 to a median fair value of $37.08, indicating the market hasn't fully priced in Perrigo Company plc's earnings power. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $3.30 (-75.6%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $50.27 (+270.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +346.4% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: late-stage pipeline catalysts could provide meaningful support for Perrigo Company plc's revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: regulatory rejection risk represents a meaningful risk for Perrigo Company plc and its Drug Manufacturers - Specialty & Generic peers. |
How Does PRGO Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: TLRY · LFCR · AQST · CABR · VTRS · CBDY · CPHI · LNTH · TAK · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like PRGO on Quality?
Closest companies to PRGO’s Quality of Company score of 5.9/10, across all industries.
- HAFG — Holistic Asset Finance Group Co., Ltd. (QOC 5.9) · analysis
- DUKR — DUKE Robotics Corp. (QOC 5.9) · analysis
- TYGO — Tigo Energy, Inc. (QOC 5.9) · analysis
- WYFI — WhiteFiber, Inc. (QOC 5.9) · analysis
- SBGI — Sinclair, Inc. (QOC 5.9) · analysis
- RLAY — Relay Therapeutics, Inc. (QOC 5.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does PRGO Appear In?
So Is Perrigo Company plc (PRGO) Worth Buying in 2026?
The convergence of 5.9/10 quality, multi-model undervaluation (6/7 bullish, +173.5% median upside), and a median fair value of $37.08 vs. $13.56 current price makes Perrigo Company plc one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Perrigo Company plc's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About PRGO Stock?
Should I buy PRGO stock right now?
Based on CirclFi's multi-model analysis, 6 of 7 models see upside for PRGO at $13.56. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.9/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Perrigo Company plc?
Key risks include: limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (1422% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does PRGO compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, PRGO holds a Quality Score of 5.9/10. Comparable companies include TLRY (QOC 5.9), LFCR (QOC 5.9), AQST (QOC 6.0). The relative ranking helps investors identify whether PRGO offers better fundamental quality than alternatives in the same sector.
Is PRGO a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PRGO's Quality Score of 5.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy PRGO at?
CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $3.30 to $50.27. At $13.56, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PRGO.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad